Medical Nitrous Oxide Combined With Personalized Traumatic Script Exposure for the Treatment of Post-Traumatic Stress Disorder
NCT07927192, Phase 3, Not yet recruiting, University Hospital, Tours
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Medical Nitrous Oxide Combined With Personalized Traumatic Script Exposure for the Treatment of Post-Traumatic Stress Disorder | ClinicalTrials.gov |
| NCT number | NCT07927192 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 96 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Tours | ClinicalTrials.gov |
| Conditions | PTSD - Post Traumatic Stress Disorder | ClinicalTrials.gov |
| Interventions | MEOPA (Nitrous Oxide/Oxygen Premix), Medical Air in Oxygen, Personalized Traumatic Script Exposure | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in PTSD symptom severity measured using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) until 3 months | Day 0 and 3 months | The primary endpoint is the change in PTSD symptom severity, as assessed by the CAPS-5 scale, between baseline (Day 0, prior to treatment initiation) and the 3-month follow-up assessment. | ClinicalTrials.gov |
| Secondary | Change in PTSD symptom severity using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) until 9 months | Day 0, 3 months and 9 months | The secondary endpoint is the change in PTSD symptom severity, as assessed by the CAPS-5 scale, between baseline (Day 0, prior to treatment initiation), 3 months and the 9-month follow-up assessment. | ClinicalTrials.gov |
| Secondary | Change in depression severity using the Patient Health Questionnaire-9 (PHQ-9) until 9 months | Day 0, 3 months, 6 months and 9 months | The secondary endpoint is the change in depression severity, as assessed by the PHQ-9 scale, between baseline (Day 0, prior to treatment initiation), 3 months, 6 months and the 9-month follow-up assessment. | ClinicalTrials.gov |
| Secondary | Change in anxiety symptoms using the State-Trait Anxiety Inventory (STAI) until 9 months | Day 0, 3 months, 6 months and 9 months | The secondary endpoint is the change in anxiety symptom severity, as assessed by the STAI scale, between baseline (Day 0, prior to treatment initiation), 3 months, 6 months and the 9-month follow-up assessment. | ClinicalTrials.gov |
| Secondary | Change in PTSD symptom severity using the PTSD Checklist for DSM-5 (PCL-5) until 9 months | Day 0, 3 months, 6 months and 9 months | The secondary endpoint is the change in PTSD symptom severity, as assessed by the PCL-5 scale, between baseline (Day 0, prior to treatment initiation), 3 months, 6 months and the 9-month follow-up assessment. | ClinicalTrials.gov |
| Secondary | Change in dissociative symptoms using the Dissociative Experience Scale (DES-28) until 9 months | Day 0, 3 months, 6 months and 9 months | The secondary endpoint is the change in dissociative symptoms, as assessed by the DES-28 scale, between baseline (Day 0, prior to treatment initiation), 3 months, 6 months and the 9-month follow-up assessment. | ClinicalTrials.gov |
| Secondary | Change in functional impairment using the Functioning Assessment Short Test (FAST) until 9 months | Day 0, 3 months, 6 months and 9 months | The secondary endpoint is the change in fuctional impairment, as assessed by the FAST scale, between baseline (Day 0, prior to treatment initiation), 3 months, 6 months and the 9-month follow-up assessment. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)